BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23805156)

  • 1. Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis.
    Zheng Y; Zhang S; Tan Grahn HM; Ye C; Gong Z; Zhang Q
    Hepat Mon; 2013 Apr; 13(4):e6496. PubMed ID: 23805156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis.
    Li H; Zhang HM; Chen LF; Chen YQ; Chen L; Ren H; Hu HD
    Clin Res Hepatol Gastroenterol; 2015 Feb; 39(1):80-92. PubMed ID: 25199680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis.
    Tang W; Chen L; Zheng R; Pan L; Gao J; Ye X; Zhang X; Zheng W
    PLoS One; 2015; 10(6):e0128673. PubMed ID: 26057738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.
    Liu Z; Jiang L; Liang G; Song E; Jiang W; Zheng Y; Gong C
    J Viral Hepat; 2017 Jul; 24(7):561-572. PubMed ID: 28072494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.
    Loomba R; Rowley A; Wesley R; Liang TJ; Hoofnagle JH; Pucino F; Csako G
    Ann Intern Med; 2008 Apr; 148(7):519-28. PubMed ID: 18378948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance.
    Ziakas PD; Karsaliakos P; Mylonakis E
    Haematologica; 2009 Jul; 94(7):998-1005. PubMed ID: 19454492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis.
    Liu JY; Sheng YJ; Ding XC; Tang H; Tong SW; Zhang DZ; Zhou Z; Hu P; Liao Y; Ren H; Hu HD
    J Formos Med Assoc; 2015 Feb; 114(2):164-73. PubMed ID: 25678179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
    Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
    Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
    Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
    Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
    Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis.
    Xu Z; Dai W; Wu YT; Arshad B; Li X; Wu H; Chen HR; Wu KN; Kong LQ
    Eur J Cancer Care (Engl); 2018 Mar; 27(2):e12799. PubMed ID: 29265535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
    Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ
    J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.
    Yun J; Kim KH; Kang ES; Gwak GY; Choi MS; Lee JE; Nam SJ; Yang JH; Park YH; Ahn JS; Im YH
    Br J Cancer; 2011 Feb; 104(4):559-63. PubMed ID: 21285992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.
    Chen XQ; Peng JW; Lin GN; Li M; Xia ZJ
    Med Oncol; 2012 Jun; 29(2):1237-41. PubMed ID: 21556931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
    JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
    Hsu C; Hsiung CA; Su IJ; Hwang WS; Wang MC; Lin SF; Lin TH; Hsiao HH; Young JH; Chang MC; Liao YM; Li CC; Wu HB; Tien HF; Chao TY; Liu TW; Cheng AL; Chen PJ
    Hepatology; 2008 Mar; 47(3):844-53. PubMed ID: 18302293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
    Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
    Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis.
    Katz LH; Fraser A; Gafter-Gvili A; Leibovici L; Tur-Kaspa R
    J Viral Hepat; 2008 Feb; 15(2):89-102. PubMed ID: 18184191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
    Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
    Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.
    Lee HJ; Kim DY; Keam B; Lee JH; Han SW; Oh DY; Yoon JH; Kim TY; Kim YJ; Lee KW; Kim JW; Jeong SH; Lee JS; Kim JH; Im SA
    Breast Cancer; 2014 Jul; 21(4):387-93. PubMed ID: 23073741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.